Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A meta-analysis of randomized controlled trials

Chest

Volumn 139, Issue 5, 2011, Pages 1148-1155

  Walkey, Allan J ^a   O'Donnell, Max R ^b   Wiener, Renda Soylemez ^a,c,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79955776573     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-1556     Document Type: Article

References (43)

1. Hidron AI, Edwards JR, Patel J, et al;National Healthcare Safety Network Team;Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011.
2. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854-3862. (Pubitemid 43062645)
3. Vardakas KZ, Matthaiou DK, Falagas ME. Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J. 2009;34(5):1148-1158.
4. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13(12):1840-1846.
5. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staph ylococcus aureus in early onset ventilator-associated pneumonia. Crit Care. 2006;10(3):R97.
6. American Thoracic Society;Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
7. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphy lococcus aureus nosocomial pneumonia. Chest. 2003; 124( 5): 1789-1797. (Pubitemid 37433574)
8. Powers JH, Ross DB, Lin D, Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest. 2004;126(1):314-315.
9. Powers JH, Lin D, Ross D. FDA evaluation of antimicrobials: subgroup analysis. Chest. 2005;127(6):2298-2299.
10. Estes L, Orenstein R. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther. 2007;29(2):381-383.
11. Kalil AC, Puumala SE, Stoner J. Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest. 2004;125(6):2370-2371. (Pubitemid 38788219)
12. Bartlett JG, ed. Johns Hopkins Point of Care Information Technology Center. ABX Guide. Johns Hopkins POC-IT Center Web site. http://hopkins- abxguide.org. Accessed June 15, 2010.
13. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8(1):53-66. (Pubitemid 351620940)
14. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of grampositive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;35(1):3-12.
15. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. Cochrane Web site. www.cochrane-handbook.org. Updated September 2009. Accessed November 2009.
16. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002;31(1):150-153. (Pubitemid 34284917)
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
18. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother. 2004;53(2):335-344. (Pubitemid 38239971)
19. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphy lococcus aureus. Chest. 2008;134(6):1200-1207.
20. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007;60(6):1361-1369. (Pubitemid 350168334)
21. Lin DF, Zhang YY, Wu JF, et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents. 2008;32(3):241-249.
22. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32(3):402-412. (Pubitemid 32173626)
23. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25(3):980-992.
24. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481-1490. (Pubitemid 34553708)
25. Cepeda JA, Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother. 2004;53(2):345-355. (Pubitemid 38239972)
26. Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62(pt 1):97-128.
27. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219. (Pubitemid 36143396)
28. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996;38(5):865-869. (Pubitemid 26413723)
29. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993;37(2):281-286. (Pubitemid 23046569)
30. Luna CM, Bruno DA, García-Morato J, et al. Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets. Chest. 2009;135(6):1564-1571.
31. Boselli E, Breilh D, Rimmelé T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med. 2005;33(7):1529-1533. (Pubitemid 40980608)
32. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillinresistant Staphylococcus aureus. J Infect Dis. 2007;195(2):202-211. (Pubitemid 46080052)
33. Dumitrescu O, Boisset S, Badiou C, et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007;51(4):1515-1519. (Pubitemid 46586841)
34. Moroney SM, Heller LC, Arbuckle J, Talavera M, Widen RH. Staphylococcal cassette chromosome mec and Panton-Valentine leukocidin characterization of methicillin-resistant Staphylococcus aureus clones. J Clin Microbiol. 2007;45(3):1019-1021. (Pubitemid 46427727)
35. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002; 359(9308):753-759. (Pubitemid 34215075)
36. Mullins CD, Kuznik A, Shaya FT, et al. Cost-effectiveness analysis of linezolid compared with vancomycin for the treat ment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther. 2006;28(8):1184-1198. (Pubitemid 44376813)
37. De Cock E, Krueger WA, Sorensen S, et al. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection. 2009;37(2):123-132.
38. Grau S, Alvarez-Lerma F, del Castillo A, Neipp R, Rubio-Terrés C. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. J Chemother. 2005;17(2):203-211. (Pubitemid 40732881)
39. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med. 2004;32(1):137-143. (Pubitemid 38125575)
40. Sánchez García M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303(22):2260-2264.
41. Gaynes RP. Preserving the effectiveness of antibiotics. JAMA. 2010;303(22):2293-2294.
42. Yanagihara K, Kihara R, Araki N, et al. Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive methicillin-resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection. Int J Antimicrob Agents. 2009;34(5):477-481.
43. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest. 2005;128(4):2732-2738. (Pubitemid 41507634)